After the complete merger of Mylan and Pfizer’s subsidiary Upjohn, the new stock VTRS emerged in NASDAQ by replacing NASDAQ: MYL which was at $15.85 on Monday. Pfizer has a strong candidate for treating COVID-19 patients with a 90% success rate, hence some investors have confidence in PFE shares while Moderna claims to have a 95% efficacy.
Mylan (MYL) surged significantly since September’s last week but in long run, it couldn’t restore lost points that were the pride of shareholders from 2015. Sharp fall didn’t stop even though the company has kept attractive financial standing.
Pfizer plays a crucial role in the growth of VTRS shares while it holds significant ownership in the company and has a lot of experience in handling the biotech firm. There is a high likelihood of a correlation between PFE and VTRS. For debuting day Viatris shares are roughly possible to jump over $20.